----item----
version: 1
id: {8592DA31-6542-4610-B966-240545E2E8DB}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/11/03/Cidara plans IPO to fund antifungal pipeline
parent: {9A22D265-E46B-490A-8BDC-BA644F0271DB}
name: Cidara plans IPO to fund antifungal pipeline
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 82261dbb-79c2-4968-9b10-2e3d18b1cda6

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{B3122C5E-FF3F-438A-9C93-1B54DC1286A5}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 44

Cidara plans IPO to fund antifungal pipeline
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 44

Cidara plans IPO to fund antifungal pipeline
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1380

<p>Cidara Therapeutics, a San Diego firm focused on developing novel antifungals, both standard small molecules and bispecific molecules based on its immunotherapy technology platform, has filed a prospectus with the SEC for an initial public offering on Nasdaq of up to $69m, with net proceeds of up to $61.4m including full exercise of an over-allotment option. The firm, whose CEO Jeffrey Stein was formerly CEO of Cubist acquisition Trius Therapeutics, will invest the money into clinical development of the intravenous and topical forms of CD101 in candidemia/invasive candidiasis and acute and recurrent vulvovaginal candidiasis, respectively, through to the completion of Phase II trials, and the initiation of a pivotal Phase III trial of the topical product. It will also invest in the preclinical and early clinical studies of candidates from its Cloudbreak immunotherapy platform, and to expand that platform to other areas of infectious disease. Cidara <a href="http://www.scripintelligence.com/business/Laguna-raises-30m-as-2015-VC-funding-momentum-continues-356799" target="_new">recently closed a $42m series B fundraising</a>.</p><p><b>Related Scrip content:</b></p><p><a href="http://www.scripintelligence.com/business/Cidara-CEO-Stein-brings-Trius-gang-biotech-vets-together-352587" target="_new">Cidara CEO Stein brings Trius gang, biotech vets together</a></p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 1020

<p>Cidara Therapeutics, a San Diego firm focused on developing novel antifungals, both standard small molecules and bispecific molecules based on its immunotherapy technology platform, has filed a prospectus with the SEC for an initial public offering on Nasdaq of up to $69m, with net proceeds of up to $61.4m including full exercise of an over-allotment option. The firm, whose CEO Jeffrey Stein was formerly CEO of Cubist acquisition Trius Therapeutics, will invest the money into clinical development of the intravenous and topical forms of CD101 in candidemia/invasive candidiasis and acute and recurrent vulvovaginal candidiasis, respectively, through to the completion of Phase II trials, and the initiation of a pivotal Phase III trial of the topical product. It will also invest in the preclinical and early clinical studies of candidates from its Cloudbreak immunotherapy platform, and to expand that platform to other areas of infectious disease. Cidara <a>recently closed a $42m series B fundraising</a>.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 44

Cidara plans IPO to fund antifungal pipeline
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151103T120000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151103T120000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151103T120000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028126
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 44

Cidara plans IPO to fund antifungal pipeline
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 11

Expert View
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357223
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042311Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

82261dbb-79c2-4968-9b10-2e3d18b1cda6
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042311Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
